MA39193A1 - Modulateurs du gpr6 à base de tétrahydropyridopyrazines - Google Patents
Modulateurs du gpr6 à base de tétrahydropyridopyrazinesInfo
- Publication number
- MA39193A1 MA39193A1 MA39193A MA39193A MA39193A1 MA 39193 A1 MA39193 A1 MA 39193A1 MA 39193 A MA39193 A MA 39193A MA 39193 A MA39193 A MA 39193A MA 39193 A1 MA39193 A1 MA 39193A1
- Authority
- MA
- Morocco
- Prior art keywords
- tetrahydropyridopyrazines
- gpr6
- modulators based
- gpr6 modulators
- compounds
- Prior art date
Links
- HOFCYSNYAFJTSI-UHFFFAOYSA-N 1,2,3,4-tetrahydropyrido[2,3-b]pyrazine Chemical class C1=CC=C2NCCNC2=N1 HOFCYSNYAFJTSI-UHFFFAOYSA-N 0.000 title 1
- 101150014072 Gpr6 gene Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La présente invention concerne des composés de formule (i) : qui sont utiles comme modulateurs du gpr6, des compositions pharmaceutiques les contenant, des procédés de traitement de maladies associées au gpr6, et des procédé de fabrication des composés et de leurs intermédiaires.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361919661P | 2013-12-20 | 2013-12-20 | |
| PCT/US2014/071543 WO2015095728A1 (fr) | 2013-12-20 | 2014-12-19 | Modulateurs du gpr6 à base de tétrahydropyridopyrazines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA39193A1 true MA39193A1 (fr) | 2017-06-30 |
| MA39193B1 MA39193B1 (fr) | 2018-04-30 |
Family
ID=52440811
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA39193A MA39193B1 (fr) | 2013-12-20 | 2014-12-19 | Modulateurs du gpr6 à base de tétrahydropyridopyrazines |
Country Status (42)
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2794565B1 (fr) | 2011-12-21 | 2017-07-26 | Novira Therapeutics Inc. | Agents antiviraux de l'hépatite b |
| US9487526B2 (en) | 2012-08-13 | 2016-11-08 | Takeda Pharmaceutical Company Limited | Quinoxaline derivatives as GPR6 modulators |
| CA2881057C (fr) | 2012-08-28 | 2020-10-27 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides et leur utilisation en tant que medicaments dans le traitement de l'hepatite b |
| JP6466348B2 (ja) | 2013-02-28 | 2019-02-06 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | スルファモイル−アリールアミドおよびb型肝炎を処置するための医薬品としてのその使用 |
| HUE033542T2 (en) | 2013-04-03 | 2017-12-28 | Janssen Sciences Ireland Uc | Their use as medicaments for the treatment of N-phenylcarboxamide derivatives and hepatitis B |
| TW202126620A (zh) | 2013-05-17 | 2021-07-16 | 愛爾蘭商健生科學愛爾蘭無限公司 | 胺磺醯基吡咯醯胺衍生物及其作為用於治療b型肝炎藥物的用途 |
| HUE040446T2 (hu) | 2013-05-17 | 2019-03-28 | Janssen Sciences Ireland Uc | Szulfamoiltiofenamid-származékok és gyógyszerként történõ alkalmazásuk hepatitis B kezelésére |
| WO2015011281A1 (fr) | 2013-07-25 | 2015-01-29 | Janssen R&D Ireland | Dérivés de pyrrolamide à substitution glyoxamide et leur utilisation en tant que médicaments pour le traitement de l'hépatite b |
| MX368158B (es) | 2013-10-23 | 2019-09-20 | Janssen Sciences Ireland Uc | Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b. |
| JO3466B1 (ar) * | 2013-12-20 | 2020-07-05 | Takeda Pharmaceuticals Co | مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6 |
| US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| JP6553059B2 (ja) | 2014-02-05 | 2019-07-31 | ノヴィラ・セラピューティクス・インコーポレイテッド | Hbv感染の治療のための併用療法 |
| PL3102572T3 (pl) | 2014-02-06 | 2019-04-30 | Janssen Sciences Ireland Uc | Pochodne sulfamoilopirolamidu i ich zastosowanie jako leki do leczenia wirusowego zapalenia wątroby typu B |
| JP6526034B2 (ja) * | 2014-02-14 | 2019-06-05 | 武田薬品工業株式会社 | Gpr6のピリドピラジンモジュレーター |
| EP3271019A1 (fr) | 2015-03-19 | 2018-01-24 | Novira Therapeutics Inc. | Dérivés d'azocane et d'azonane, et méthodes de traitement d'infections provoquées par le virus de l'hépatite b |
| US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| AR106192A1 (es) | 2015-09-29 | 2017-12-20 | Novira Therapeutics Inc | Formas cristalinas de un agente antiviral contra la hepatitis b |
| WO2017181141A2 (fr) | 2016-04-15 | 2017-10-19 | Novira Therapeutics, Inc. | Associations et méthodes comprenant un inhibiteur d'ensemble capside |
| JOP20180057A1 (ar) * | 2017-06-15 | 2019-01-30 | Takeda Pharmaceuticals Co | مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6 |
| SG11202007097QA (en) | 2018-03-14 | 2020-08-28 | Janssen Sciences Ireland Unlimited Co | Capsid assembly modulator dosing regimen |
| AU2020223865A1 (en) | 2019-02-22 | 2021-07-15 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases |
| BR112021021454A2 (pt) | 2019-05-06 | 2021-12-21 | Janssen Sciences Ireland Unlimited Co | Derivados de amida úteis no tratamento da infecção por hbv ou doenças induzidas por hbv |
| EP4568668A4 (fr) * | 2022-08-11 | 2026-07-29 | Maplight Therapeutics Inc | Agonistes inverses de gpr6 |
| WO2026067262A1 (fr) * | 2024-09-26 | 2026-04-02 | 四川科伦药物研究院有限公司 | Composé à cycles fusionnés, composition pharmaceutique le comprenant, utilisation et procédé |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6114139A (en) * | 1994-08-11 | 2000-09-05 | Takeda Chemical Industries, Ltd. | G-protein coupled receptor protein and a DNA encoding the receptor |
| CN1364167A (zh) * | 1999-02-26 | 2002-08-14 | 阿瑞那制药公司 | G蛋白偶联受体6的小分子调节剂 |
| WO2001070269A1 (fr) | 2000-03-24 | 2001-09-27 | Akzo Nobel N.V. | Inhibiteurs de la croissance des keratinocytes et derives d'acide hydroxamique |
| WO2004038416A1 (fr) * | 2002-10-24 | 2004-05-06 | Bayer Healthcare Ag | Diagnostic et therapeutique de maladies associees au recepteur 6 couple a la proteine g humain (gpr6) |
| JP2006516573A (ja) | 2003-01-31 | 2006-07-06 | メルク エンド カムパニー インコーポレーテッド | 糖尿病の治療および予防のためのジペプチジルペプチダーゼ阻害薬としての3−アミノ−4−フェニルブタン酸誘導体 |
| SE0400285D0 (sv) * | 2004-02-10 | 2004-02-10 | Astrazeneca Ab | Pyrroloquinoline and piperidoquinoline derivatives, preparation thereof, compositions containing them and uses thereof |
| US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| DK2013208T3 (da) * | 2006-04-21 | 2011-08-15 | Pfizer Prod Inc | Pyridin[3,4-B]pyrazinoner |
| WO2007125405A2 (fr) | 2006-05-01 | 2007-11-08 | Pfizer Products Inc. | Composés hétérocycliques 2-amino-substitués à cycles fusionnés |
| WO2008149153A1 (fr) | 2007-06-05 | 2008-12-11 | Astrium Limited | Système et procédé de test à distance |
| GB0710844D0 (en) | 2007-06-06 | 2007-07-18 | Lectus Therapeutics Ltd | Potassium ion channel modulators & uses thereof |
| GB2449929A (en) | 2007-06-08 | 2008-12-10 | Snell & Wilcox Ltd | Hierarchical spatial resolution building processes to fill holes in an interpolated image |
| CN102625804B (zh) | 2009-06-12 | 2015-04-08 | Abivax公司 | 用于治疗aids的化合物 |
| WO2013087815A1 (fr) | 2011-12-15 | 2013-06-20 | Merz Pharma Gmbh & Co. Kgaa | Composition pharmaceutique liquide contenant un dérivé de pyrazolopyrimidine et utilisations pharmaceutiques de celle-ci |
| WO2013087808A1 (fr) | 2011-12-15 | 2013-06-20 | Merz Pharma Gmbh & Co. Kgaa | Composition pharmaceutique comprenant une pyrazolopyrimidine et une cyclodextrine |
| WO2013169964A1 (fr) | 2012-05-09 | 2013-11-14 | Sunovion Pharmaceuticals Inc. | Composés hétéroaryles et leurs procédés d'utilisation |
| US9487526B2 (en) | 2012-08-13 | 2016-11-08 | Takeda Pharmaceutical Company Limited | Quinoxaline derivatives as GPR6 modulators |
| FR2995937B1 (fr) | 2012-09-21 | 2014-09-26 | Exoes | Ensemble de production d'electricite a moteur a pression de vapeur |
| JO3466B1 (ar) * | 2013-12-20 | 2020-07-05 | Takeda Pharmaceuticals Co | مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6 |
-
2014
- 2014-12-18 JO JOP/2014/0369A patent/JO3466B1/ar active
- 2014-12-19 SM SM20180668T patent/SMT201800668T1/it unknown
- 2014-12-19 MY MYPI2016001142A patent/MY177031A/en unknown
- 2014-12-19 AR ARP140104807A patent/AR098872A1/es active IP Right Grant
- 2014-12-19 JP JP2016541330A patent/JP6538697B2/ja active Active
- 2014-12-19 ES ES14833425T patent/ES2702187T3/es active Active
- 2014-12-19 DK DK14833425.3T patent/DK3083620T3/en active
- 2014-12-19 US US14/577,480 patent/US9181249B2/en active Active
- 2014-12-19 UA UAA201606659A patent/UA120427C2/uk unknown
- 2014-12-19 PE PE2016000838A patent/PE20160751A1/es unknown
- 2014-12-19 CR CR20160321A patent/CR20160321A/es unknown
- 2014-12-19 CN CN201810356710.6A patent/CN108658978A/zh active Pending
- 2014-12-19 RS RS20181548A patent/RS58092B1/sr unknown
- 2014-12-19 NZ NZ721723A patent/NZ721723A/en unknown
- 2014-12-19 HR HRP20182004TT patent/HRP20182004T1/hr unknown
- 2014-12-19 KR KR1020167019644A patent/KR102441531B1/ko active Active
- 2014-12-19 TN TN2016000244A patent/TN2016000244A1/en unknown
- 2014-12-19 SG SG11201604921TA patent/SG11201604921TA/en unknown
- 2014-12-19 EP EP18187138.5A patent/EP3453709A1/fr not_active Withdrawn
- 2014-12-19 SI SI201430995T patent/SI3083620T1/sl unknown
- 2014-12-19 EP EP14833425.3A patent/EP3083620B1/fr active Active
- 2014-12-19 HU HUE14833425A patent/HUE042443T2/hu unknown
- 2014-12-19 GE GEAP201414210A patent/GEP201706783B/en unknown
- 2014-12-19 CA CA2934247A patent/CA2934247C/fr active Active
- 2014-12-19 TW TW110118089A patent/TWI809395B/zh active
- 2014-12-19 BR BR112016014020-6A patent/BR112016014020B1/pt active IP Right Grant
- 2014-12-19 CN CN201480069550.7A patent/CN105829309B/zh active Active
- 2014-12-19 UY UY0001035908A patent/UY35908A/es not_active Application Discontinuation
- 2014-12-19 MA MA39193A patent/MA39193B1/fr unknown
- 2014-12-19 WO PCT/US2014/071543 patent/WO2015095728A1/fr not_active Ceased
- 2014-12-19 LT LTEP14833425.3T patent/LT3083620T/lt unknown
- 2014-12-19 TW TW103144660A patent/TWI730937B/zh active
- 2014-12-19 PT PT14833425T patent/PT3083620T/pt unknown
- 2014-12-19 EA EA201691272A patent/EA032443B1/ru unknown
- 2014-12-19 AU AU2014368992A patent/AU2014368992C1/en active Active
- 2014-12-19 TR TR2019/00038T patent/TR201900038T4/tr unknown
- 2014-12-19 MX MX2016008188A patent/MX2016008188A/es active IP Right Grant
- 2014-12-19 PL PL14833425T patent/PL3083620T4/pl unknown
-
2015
- 2015-10-14 US US14/883,174 patent/US9708313B2/en active Active
-
2016
- 2016-06-13 IL IL24617716A patent/IL246177B/en active IP Right Grant
- 2016-06-17 PH PH12016501192A patent/PH12016501192B1/en unknown
- 2016-06-17 DO DO2016000144A patent/DOP2016000144A/es unknown
- 2016-06-20 CL CL2016001595A patent/CL2016001595A1/es unknown
- 2016-07-08 ZA ZA2016/04703A patent/ZA201604703B/en unknown
- 2016-07-20 EC ECIEPI201661758A patent/ECSP16061758A/es unknown
-
2017
- 2017-06-13 US US15/621,761 patent/US10077266B2/en active Active
-
2018
- 2018-08-07 US US16/057,350 patent/US10738046B2/en active Active
-
2019
- 2019-01-03 CY CY20191100008T patent/CY1121395T1/el unknown
-
2023
- 2023-06-15 AR ARP230101544A patent/AR129635A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA39193B1 (fr) | Modulateurs du gpr6 à base de tétrahydropyridopyrazines | |
| MA34968B1 (fr) | Urées asymétriques et utilisations médicales de celles-ci | |
| MA35920B1 (fr) | Composés destinés au traitement de l'amyotrophie spinale | |
| MA42109A (fr) | Amides hétérocycliques utilisés en tant qu'inhibiteurs de kinase | |
| MX388682B (es) | Compuestos agonistas de gpr119 y metodo para tratar enfermedades y afecciones mediado a traves de gpr119. | |
| JOP20220119A1 (ar) | أجسام مضادة trem2 واستخداماتها | |
| MA37959A2 (fr) | Dérivés de 5-phénoxy-3h-pyrimidin-4-one et leur utilisation en tant qu'inhibiteurs de la transcriptase inverse du vih | |
| EA201790070A1 (ru) | Бифениламиды, содержащие модифицированные простые эфирные группы, в качестве ингибиторов hsp90 и стимуляторов hsp70 | |
| EA201690153A1 (ru) | Замещенные бензофуранильные и бензоксазолильные соединения и их применения | |
| EA201890239A3 (ru) | Фумараты как пролекарства и их применение при лечении различных заболеваний | |
| EA201790273A1 (ru) | Флагеллиновые композиции и их применение | |
| MX353706B (es) | Anticuerpos contra csf-1r humano y usos de los mismos. | |
| MA39211B1 (fr) | Composés tricycliques comme agents anti-cancers | |
| EA201500403A1 (ru) | Соединения, активирующие теломеразу, и способы их применения | |
| MA39152B1 (fr) | Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine | |
| MX2018007075A (es) | Compuestos policiclicos como inhibidores de tirosina quinasa de bruton. | |
| EA201691141A1 (ru) | Соединения против ccr6 | |
| PH12019501362A1 (en) | Polymorphs | |
| BR112014013138A2 (pt) | anilinas substituídas como antagonistas de ccr(4) | |
| EA201890898A1 (ru) | Новые соединения и конъюгаты криптофицина, их получение и их терапевтическое применение | |
| EA201790570A1 (ru) | Модуляторы р2х7 | |
| MA40875A (fr) | 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux | |
| MA39337A1 (fr) | Modulateurs de pyrazines de gpr6 | |
| PH12020550947A1 (en) | Polymorphs | |
| MA40366A (fr) | Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines |